Advertisement

Treating schizophrenia at the time of menopause

      Abstract

      The purpose of this review is to optimize treatment for women with schizophrenia during the menopause. Recommendations are based on a relatively sparse literature derived from searching PubMed, PsychINFO, SOCINDEX with appropriate search terms for all years subsequent to 2000. Attention needs to be paid to menopausal symptoms in women with schizophrenia and to the possibility that psychotic symptoms may worsen at this time and that general health may deteriorate. Antipsychotic treatment may need to be modified and cardiac and metabolic health indices closely monitored.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bergemann N.
        • Parzer P.
        • Nagl I.
        • et al.
        Acute psychiatric admission and menstrual cycle phase in women with schizophrenia.
        Arch Womens Ment Health. 2002; 5: 119-126
        • Kohen D.
        • Wildgust H.J.
        The evolution of hyperprolactinaemia as an entity in psychiatric patients.
        J Psychopharmacol. 2008; 22: 6-11
        • Ayd F.J.
        Prolonged administration of chlorpromazine (thorazine) hydrochloride.
        J Am Med Assoc. 1959; 169: 1296-1301
        • Beumont P.J.
        • Corker C.S.
        • Friesen H.G.
        • et al.
        The effects of phenothiazines on endocrine function: II. Effects in men and post-menopausal women.
        Br J Psychiatry. 1974; 124: 420-430
        • Seeman M.V.
        Antipsychotic-induced amenorrhea.
        J Ment Health. 2011; 20: 484-491
        • Vasudevan N.
        • Pfaff D.W.
        Non-genomic actions of estrogens and their interaction with genomic actions in the brain.
        Front Neuroendocrinol. 2008; 29: 238-257
        • Nilsson B-O.
        • Olde B.
        • Leeb-Lundberg L.M.F.
        G protein-coupled oestrogen receptor 1 (GPER1)/GPR30: a new player in cardiovascular and metabolic oestrogenic signalling.
        Br J Pharmacol. 2011; 163: 1131-1139
        • Azcoita I.
        • Arevalo M-A.
        • De Nicola A.F.
        • Garcia-Segura L.M.
        Neuroprotective actions of estradiol revisited.
        Trends Endocrinol Metab. 2011; 22: 467-473
        • Bergemann N.
        • Parzer P.
        • Runnebaum B.
        • Resch F.
        • Mundt C.
        Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia.
        Psychol Med. 2007; 37: 1427-1436
        • Riecher-Rössler A.
        • Häfner H.
        • Stumbaum M.
        • Maurer K.
        • Schmidt R.
        Can estradiol modulate schizophrenic symptomatology.
        Schizophr Bull. 1994; 20: 203-214
        • Riecher-Rössler A.
        • Kulkarni J.
        Estrogens and gonadal function in schizophrenia and related psychoses.
        Curr Top Behav Neurosci. 2011; 8: 155-171
        • Seeman M.V.
        Menstrual exacerbation of schizophrenia symptoms.
        Acta Psychiatr Scand. 2012; ([Epub ahead of print]; January 12)
        • Sit D.
        • Rothschild A.J.
        • Wisner K.L.
        A review of postpartum psychosis.
        J Womens Health (Larchmt). 2006; 15: 352-368
        • Kraepelin E.
        Dementia praecox and paraphrenia. Psychiatrie: ein lehrbuch fur studierende und artze.
        4th ed. JA Barth, Leipzig1893
        • Häfner H.
        • Ehrenreich H.
        • Gattaz W.F.
        • Louza M.R.
        • Riecher-Rössler A.
        • Kulkarni J.
        Oestrogen—a protective factor in schizophrenia.
        Curr Psychiatry Rev. 2006; 2: 339-352
        • Kulkarni J.
        • de Castella A.
        • Fitzgerald P.
        • et al.
        Estrogen in severe mental illness. A potential new treatment approach.
        Arch Gen Psychiatry. 2008; 65: 955-960
        • Kulkarni J.
        Oestrogen—a new treatment approach for schizophrenia?.
        Med J Aust. 2009; 190: S37-S38
        • Richardson M.K.
        The Women's Health Initiative tells us more about what estrogen can and cannot do but does not give us the answer.
        Menopause. 2010; 17: 235-236
        • Banks E.
        • Canfell K.
        Hormone therapy risks and benefits—the Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.
        Am J Epidemiol. 2009; 170: 24-28
        • Usall J.
        • Huerta-Ramos E.
        • Iniesta R.
        • et al.
        Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.
        J Clin Psychiatry. 2011; 72: 1552-1557
        • Canuso C.M.
        • Pandina G.
        Gender and schizophrenia.
        Psychopharmacol Bull. 2007; 40: 178-190
        • Sajatovic M.
        • Donenwirth K.
        • Sultana D.
        • Buckley P.
        Admissions, length of stay, and medication use among women in an acute care state psychiatric facility.
        Psychiatr Serv. 2000; 51: 1278-1281
        • Sajatovic M.
        • Rosenthal M.B.
        • Plax M.S.
        • Meyer M.L.
        • Bingham C.R.
        Mental illness and menopause: a patient and family perspective.
        J Gend Specif Med. 2003; 6: 31-34
        • Friedman S.H.
        • Sajatovic M.
        • Schuermeyer I.N.
        • et al.
        Menopause-related quality of life in chronically mentally ill women.
        Int J Psychiatry Med. 2005; 35: 259-271
        • Usall J.
        • Haro J.M.
        • Araya S.
        • et al.
        Social functioning in schizophrenia: what is the influence of gender.
        Eur J Psychiatry. 2007; 21: 199-205
        • Grossman L.S.
        • Harrow M.
        • Rosen C.
        • Faull R.
        • Strauss G.P.
        Sex differences in schizophrenia and other psychotic disorders: a 20-year longitudinal study of psychosis and recovery.
        Compr Psychiatry. 2008; 49: 523-529
        • Newcomer J.W.
        Medical risk in patients with bipolar disorder and schizophrenia.
        J Clin Psychiatry. 2006; 67: 25-30
        • Butler L.
        • Santoro N.
        The reproductive endocrinology of the menopausal transition.
        Steroids. 2011; 76: 627-635
        • Thilers P.P.
        • MacDonald S.W.S.
        • Nilsson L.-G.
        • Herlitz A.
        Accelerated postmenopausal cognitive decline is restricted to women with normal BMI: Longitudinal evidence from the Betula project.
        Psychoneuroendocrinology. 2010; 35: 516-524
        • Halari R.
        The relationship of sex hormones and cortisol with cognitive functioning in schizophrenia.
        J Psychopharmacol. 2004; 18: 366-374
        • Sajatovic M.
        • Friedman S.H.
        • Schuermeyer I.N.
        • et al.
        Menopause knowledge and subjective experience among peri- and postmenopausal women with bipolar disorder, schizophrenia and major depression.
        J Nerv Ment Dis. 2006; 194: 173-178
        • Barceló M.
        • Villalta V.
        • Serrano A.
        • Araya S.
        • Ochoa S.
        • Usall J.
        Influence of menopause and gender on neuropsychological functioning in outpatients with schizophrenia.
        Psiq Biol. 2007; 14: 187-193
        • Arad M.
        • Weiner I.
        Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17β-estradiol: an animal model of menopausal psychosis?.
        Neuropsychopharmacology. 2010; 35: 1570-1582
        • Arad M.
        • Weiner I.
        Abnormally rapid reversal learning and reduced response to antipsychotic drugs following ovariectomy in female rats.
        Psychoneuroendocrinology. 2012; 37: 200-212
        • Bergemann N.
        • Mundt C.
        • Parzer P.
        • et al.
        Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study.
        Schizophr Res. 2005; 74: 125-134
        • Salokangas R.K.
        Gender and the use of neuroleptics in schizophrenia.
        Schizophr Res. 2004; 66: 41-49
        • Lindamer L.A.
        • Buse D.C.
        • Lohr J.B.
        • Jeste D.V.
        Hormone replacement therapy in postmenopausal women with schizophrenia, positive effect on negative symptoms?.
        Biol Psychiatry. 2001; 49: 47-51
        • Grover S.
        • Talwar P.
        • Baghel R.
        • et al.
        Genetic variability in estrogen disposition: potential clinical implications for neuropsychiatric disorders.
        Am J Med Genet B. 2010; 153B: 1391-1410
        • Sajatovic M.
        • Friedman S.H.
        • Sabharwal J.
        • Bingham C.R.
        Clinical characteristics and length of hospital stay among older adults with bipolar disorder, schizophrenia or schizoaffective disorder, depression, and dementia.
        J Geriatr Psychiatry Neurol. 2004; 17: 3-8
        • Rubinow D.R.
        • Moore M.
        Sex-dependent modulation of treatment response.
        Dialogues Clin Neurosci. 2004; 6: 39-51
        • Klotz U.
        Pharmacokinetics and drug metabolism in the elderly.
        Drug Metab Rev. 2009; 41: 67-76
        • Quintas L.E.M.
        • Gram K.R.S.
        • da Silveira G.P.E.
        • Lopes D.V.S.
        • Pôças E.S.C.
        Pharmacokinetic modifications and drug-drug interactions in clinical monitoring of the elderly: a short review.
        Pharm Anal Acta. 2011; 2: 141
        • Dorne J.L.
        • Walton K.
        • Renwick A.G.
        Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment.
        Food Chem Toxicol. 2003; 41: 201-224
        • Shi S.
        • Klotz U.
        Age-related changes in pharmacokinetics.
        Curr Drug Metab. 2011; 12: 601-610
        • Sagud M.
        • Mihaljević-Peles A.
        • Mück-Seler D.
        • et al.
        Smoking and schizophrenia.
        Psychiatr Danub. 2009; 21: 371-375
        • Riecher-Rössler A.
        • de Geyter C.
        The forthcoming role of treatment with oestrogens in mental health.
        Swiss Med Wkly. 2007; 137: 565-572
        • Kulkarni J.
        • Hayes E.
        • Gavrilidis E.
        Hormones and schizophrenia.
        Curr Opin Psychiatry. 2012; ([Epub ahead of print]; January 13)
        • Hiemke C.
        • Baumann P.
        • Bergemann N.
        • et al.
        AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.
        Pharmacopsychiatry. 2011; 44: 195-235
        • Usall J.
        • Barcelo M.
        • Marquez M.
        Women and schizophrenia: sex-based pharmacotherapy.
        Curr Psychiatry Rev. 2006; 2: 95-101
        • Al-Khatib S.M.
        • Allen LaPointe N.M.
        • Kramer J.M.
        • Califf R.M.
        What clinicians should know about the QT interval.
        JAMA. 2003; 289: 2120-2127
        • Zhang Y.
        • Ouyang P.
        • Post W.S.
        • et al.
        Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis.
        Am J Epidemiol. 2011; 15: 403-411
        • Turrone P.
        • Seeman M.V.
        • Silvestri S.
        Estrogen receptor activation and tardive dyskinesia.
        Can J Psychiatry. 2000; 45: 288-290
        • Raja M.
        Clozapine safety, 35 years later.
        Curr Drug Saf. 2011; 6: 164-184
        • Shi S.
        • Klotz U.
        Drug interactions with herbal medicines.
        Clin Pharmacokinet. 2012; 51: 77-104